Table 4.
AD—Alzheimer disease.
*There was no significant difference across all regions in the number of patients with AD physicians reported in their practices (P = .999).
†There was a significant difference across all regions in percentage of patients with AD taking cholinesterase inhibitors (P = .009). All comparisons between regions with and without formulary coverage for cholinesterase inhibitors were significantly different (P < .035); comparisons between regions with similar formulary coverage were not significant (P > .35).